Evotec drug extends sleep in mid-stage trial
Evotec has given a thumb's up on its Phase II data on its insomnia drug EVT 201. In the trial of 149 patients over the age of 65 researchers found that the lower dose extended sleep time by nine percent while the higher dose led to a 17 percent increase in sleep time.
- see this release on the trial
Related Articles:
Insomnia market attracts drug developers. Report
PerkinElmer acquires Evotec Tech in cash buyout. Report
Evotec adds drugs in Renovis buyout. Report
Evotec shutters Alzheimer's development program. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
